Intravitreal bevacizumab (Avastin) for subretinal neovascularization secondary to type 2A idiopathic juxtafoveal telangiectasia

Subrata Mandal; Pradeep Venkatesh; Zahir Abbas; Rajpal Vohra; Satpal Garg

首页> 外文期刊>Graefe's Archive for Clinical and Experimental Ophthalmology >Intravitreal bevacizumab (Avastin) for subretinal neovascularization secondary to type 2A idiopathic juxtafoveal telangiectasia

【24h】

Intravitreal bevacizumab (Avastin) for subretinal neovascularization secondary to type 2A idiopathic juxtafoveal telangiectasia

机译：玻璃体内贝伐单抗（Avastin）用于继发于2A型特发性近中眼凹毛细血管扩张的视网膜下新生血管形成

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

To evaluate the efficacy and safety of intravitreal bevacizumab (Avastin) in the treatment of subretinal neovascularization (SRNV) secondary to type 2A idiopathic juxtafoveal telangiectasia (IJT).

机译：评估玻璃体内贝伐单抗（Avastin）在继发于2A型特发性近凹性中心凹毛细血管扩张（IJT）的视网膜下新生血管形成（SRNV）中的疗效和安全性。

著录项

来源
《Graefe's Archive for Clinical and Experimental Ophthalmology》 |2007年第12期|1825-1829|共5页
作者
Subrata Mandal; Pradeep Venkatesh; Zahir Abbas; Rajpal Vohra; Satpal Garg;
展开▼
作者单位

Dr. Rajendra Prasad Centre for Ophthalmic Sciences All India Institute of Medical Sciences New Delhi 110029 India;

Dr. Rajendra Prasad Centre for Ophthalmic Sciences All India Institute of Medical Sciences New Delhi 110029 India;

Dr. Rajendra Prasad Centre for Ophthalmic Sciences All India Institute of Medical Sciences New Delhi 110029 India;

Dr. Rajendra Prasad Centre for Ophthalmic Sciences All India Institute of Medical Sciences New Delhi 110029 India;

Dr. Rajendra Prasad Centre for Ophthalmic Sciences All India Institute of Medical Sciences New Delhi 110029 India;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词
Bevacizumab; Subretinal neovascularization; Idiopathic juxtafoveal telangiectasia (IJT);

机译：贝伐单抗;视网膜下新生血管形成;特发性近中眼凹状毛细血管扩张（IJT）;

相似文献

外文文献
中文文献
专利

1. Intravitreal ranibizumab and bevacizumab for bilateral subretinal neovascularization secondary to idiopathic juxtafoveal telangiectasia type 2A [J] . Nikolaos Mavrakanas, Efstratios Mend-rinos, Constantin J. Pournaras Joel Salzmann Acta ophthalmologica Scandinavica . 2009,第8期

机译：玻璃体腔内兰尼单抗和贝伐单抗用于继发于2A特发性近中眼凹毛细血管扩张的双侧视网膜下新生血管形成
2. LONG-TERM OUTCOMES OF INTRAVITREAL BEVACIZUMAB THERAPY FOR SUBRETINAL NEOVASCULARIZATION SECONDARY TO IDIOPATHIC MACULAR TELANGIECTASIA TYPE 2 [J] . Toygar Okan, Guess Matthew G., Youssef David S., Retina . 2016,第11期

机译：继发于贝伐他珠单抗治疗继发于2型特发性黄斑部球囊炎的继发于视网膜下神经结膜的长期结果
3. Combined photodynamic therapy and intravitreal bevacizumab as primary treatment for subretinal neovascularization associated with type 2 idiopathic macular telangiectasia [J] . Pukhraj Rishi, Ekta Rishi, Daraius Shroff Indian Journal of Ophthalmology . 2009,第3期

机译：结合光动力疗法和玻璃体内贝伐单抗作为与2型特发性黄斑毛细血管扩张相关的视网膜下新生血管的主要治疗方法
4. Clinical Features of Treated and Untreated Type 1 Idiopathic Macular Telangiectasia Without the Occurrence of Secondary Choroidal Neovascularization Followed for 2 Years in Japanese Patients [D] . 逢坂理恵 2019

机译：在日本患者中治疗和未治疗的1型特发性黄斑部毛细血管扩张症的临床特征为继发性脉络膜新血管形成，随访2年
5. Efficacy of Intravitreal Bevacizumab in Treatment of Proliferative Type 2 Idiopathic Juxtafoveal Telangiectasia [O] . Ökkeş Baz, İhsan Yılmaz, Cengiz Alagöz, 2017

机译：玻璃体内贝伐单抗治疗增生性2型特发性近中凹窦性毛细血管扩张症的疗效
6. Intravitreal ranibizumab and bevacizumab for bilateral subretinal neovascularization secondary to idiopathic juxtafoveal telangiectasia type 2A [O] . Mavrakanas Nikolaos, Mendrinos Efstratios, Pournaras Constantin, 2009

机译：玻璃体腔内兰尼单抗和贝伐单抗用于继发于2A特发性近中眼凹毛细血管扩张的双边视网膜下新生血管

Intravitreal bevacizumab (Avastin) for subretinal neovascularization secondary to type 2A idiopathic juxtafoveal telangiectasia

摘要

著录项

相似文献

相关主题

期刊订阅